- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Myeloproliferative Neoplasm With 10% Blasts or Higher in Hungary
Total 9 results
-
Onconova Therapeutics, Inc.TerminatedMyelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEBUnited States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Kartos Therapeutics, Inc.TerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
-
UCB Biopharma S.P.R.L.Pharm Research Associates (UK) Ltd.CompletedEpilepsy With POS With or Without Secondary GeneralizationDenmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
AmgenCompletedAny Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical TrialCanada, Spain, United States, Germany, Austria, France, Greece, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Switzerland, United Kingdom
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Novartis PharmaceuticalsRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host DiseaseKorea, Republic of, Italy, Belgium, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...